Specialty Pharmacy

Emicizumab-kxwh is an antibody that activates the natural coagulation process in people with hemophilia A who lack factor VIII.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Specialty pharmacies play a vital role in the patient journey from diagnosis to treatment.

Top news of the day from across the health care landscape.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

In a study presented at ASCO, Cemiplimab shows substantial activity and durable responses with an acceptable safety profile in treatment of metastatic cutaneous squamous cell carcinoma.

Pegfilgrastim-jmdb is the first biosimilar to pegfilgrastim (Neulasta) approved by the FDA.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

American Society of Health-System Pharmacists board votes unanimously to create a new section of practitioners that will help members provide optimal patient care and medication therapy management in specialty pharmacy.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the importance of setting up organizations for success through effective education.

Medication nonadherence in the United States reportedly costs the health care system $300 billion annually, but is this figure accurate?

Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.

Durvalumab, an FDA-approved immunotherapy, met its second primary endpoint of overall survival in the phase 3 PACIFIC trial for stage 3 non-small cell lung cancer.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.

Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, and Specialty Pharmacy Times, the most read publication among specialty pharmacists, have been honored with the 2018 Hermes Creative Awards.

Ibrutinib plus obintuzumab improved progression-free survival in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The study findings add evidence to support cannabidiol’s effectiveness in reducing severe seizures in this patient population.

Top news of the day from across the health care landscape.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, talks about popular strategies employers use to control drug spending.

Investigative migraine therapy galcanezumab has reported more statistically significant benefits across multiple relevant outcomes.

Tofacitinib is the first and only Janus kinase inhibitor approved by the FDA for this patient population.

In response to the increasing incidence of colorectal cancer in young and middle-aged individuals, the American Cancer Society has updated its screening recommendations.

The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for patients with moderate or high risk of disease recurrence.

The results of a recent study provide important insights into what might influence the development of multiple sclerosis.

Top news of the day from across the health care landscape.